- Email: [email protected]
P.6.008 Treatment of pain, depressive and anxietysymptoms in fibromyalgia with venlafaxine
P6, Other topics
$3 60
[2] Blacker, D., Wilcox, M.A., Laird, N.M., Redes, L., Horvath, S.M., Go. R., etal. : Alpha-2 macroglobulin is genetically associated with AlzheimePs disease. Nat. Goner., 1998; 19: 357-360. [3] MoKeith, I.G., Ballard, C.G., Perry, R.H., Inca, RG., O'Brien, J.q2, Neill, D., etal. : Prospective validation of conceusus criteria for the diagnosis od dementia with Lewd bodies. Neurology, 2000; 54:10G0-1058.
•
Treatment of pain, depressive and anxiety symptoms in fibromyalgia with venlafaxine
B, Evren 1, C, Evren 2., M. Hosafci Guler 3 . 1Baltalimani State Hospital for Muskaloskeletal Disorders, Consultant Peyehiatrist, Istanbul, Turkey; 2Bakirkoy &ate Hospital for Mental Health and Neurological Disorders, AMATEM, Istanbal, Turkey; 3Ba#alimani State Hosp#al for Muskuloskeletal Disorders, P1weieal Therapy and ~ehab#itation Specialist, IxtanbuL Turkey
Objective: Although the pathophysiology of fibromyalgia is unknown, antidepressants have proved to be successful in alleviating symptorn~ of fibromyalgia. Aim of this study was to evaluate the efficacy of veniafaxine in the treatment of patients with fibromyaigia and depressive and anxiety symptoms commonly seen with these patients, 1VI.ethod: The study was conducted between October 2003 and March 200,4 in Naltalimani State Hospital for Musculoskeletal Disorders in Istanbuh Twenty patients with fibrorrryalgia according to the operational criteria proposed by the American College of Rheumatology were included in the study. Patients were assessed prior to and after trea~nent with fixed dose venlafaxine 75 mgtd. Second and third evaluations were in weeks 5 and 10. Pain were measured by visual analog scale and verbal analog scale and the anxiety and depression levels were measured by the Beck Depression, the Deck Anxiety, the Hamilton Anxiety and the Hamilton Depression scales. Remlts" There was a significant improvement in the mean intensity of pain and in depression and anxiety scores from baseline to week 5 and 10. The improvement in pain scores were correlated with the decrease of somatic anxiety scores measured with Hamilton Anxiety Scale. C ~ n e l ~ i o m Venlafaxine a potent inhibitor of both norepinephrine and serotonin reuptake, might be effective for both pain and comorbid depressive and anxiety symptoms independently in patients with fibromyalgia. References
O'Malley PO, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Trea~nent of fibromyalgia with antidepressants: a mats-analysis. J Gen Intern Mad. 2000 Sep;15(9):659-66. Dwi~t MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr. An open clinical trial of venlafaxine treatment of fibrornyalgia. Psy&osomatios. 1998 Jan-Feb;39(1): 14-7. Sayar K, Alcsu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Phan'nacother. 2003 Nov;37(ll):1561-5.
•
Bright light treatment in anorexia nervosa
M. Janas-Kozik 1, I. Krupka-Matuszcayk 1, M. Krzystanek 1, H i . Trzeciak 2, J . Szyrn~zal 1 . 1Nlesian Medical University,
Department and Clinic of Psychiatry and Psychotherapy, Katowice, Poland; 2Silesian Medic~ Unioersi~ Department of 2harmacology, Zatowice, Poland Bright light treatment (-BLT) was introduced for the first time to a treaCnent of seasonal affeotive disorder. Bright light synchronizes biological rhythms of human and increases serotoninergic
transmission in a brain [1], Anorexia nervosa (AN-) is a disorder with a putative increase of serotoninergic activity, Characteristic symptoms of A N are aberrant eating behavior, a desire to lose weight and fear of becoming obese, The theoretical assumption that BET may improve ~ m p t o m s of A N has never been explored be%re, The aim of the study was to assess an influence of BLT on body mass changes in AN patients during a 6 weeks of treatment, 26 female A N patients aged from 12-22 years were the examined group. 9 patients were treated with BLT and 17 were a control group. Every subsequent week of treatment the body mass index (BN3) and BMI changes were calculated and depressive symptoms assessed using Hamilton rating scale. BMI increases in each of the examined groups were observed (p<0,001). There were not statistically significant differences between BMI increases in the examined groups. A N patients with depressive symptoms showed improvement after 6 weeks (1:>=0.028). DLT may be considered effectNe in a treatment of depressive symptoms in AN. References
[1] Metzger JY, Berthou V, P~'rin P, Siohel JP (1998): Phototherapy: dininal and therapeutic evaNation of a 2-year e~perieuce. Eneephale 199% 24: 480-485. [2] Ericsson M., Poston II W.S.C., Foreyt J.F:: Common biological pathways in eating disorders and obesity. Addict. Behav. 1996, 21: 733-743.
•
Distribution of 5-HTs and 5-HT7 receptors in the human brain
K. Varnh,s 1, D.R. Thornas 2, W.D. Hirst 3, H, Hall l . 1Karolinska Instituter, Clinical Neuroscience, Psychiatry Section, Stockholm, Sweden," 2 glaxo~qm#hKline, Psychiatry Centre of Exce~ence for Drug Discovery, Harlow, United Kingdom; 3~Yyeth lResearch, Neurodegeneration Research, Princeton, N J, US.A. Purpose: The 5-HT~ and 5-HT7 receptor subtypes have been implicated in the mechanisms underlying a number of psychiatric disorders, These receptor subtypes have been suggested to be of interest for the mechanism of action of antipsychotic drugs due to the high affinity of clozapine for these binding sites, 5-HT7 receptors have also been irrplicated in anxiety and unipolar depression, Furthermore, there is evidence for the involvement of 5-HT~ and 5-HT7 receptors in cognitive functions, The aim of this study was to investigate the autoradiographio distribution of 5-HT~ and 5-HT7 receptors in the human brain, Information on the specific distribution patterns of these receptor subtypes in the human brain may clarify the different physiological functions mediated by these receptors, M.ethods: The selective and high affinity radioligands [125I]SB258585 and [IH]SB-269970 were used to study the autoradiographic distribution of 5-HT6 and 5-HT7 receptor subtypes, respectivety, in human brain whole hemisphere cryosections, Results: The 5-HT~ receptor binding sites were highly concentrated in the striatum with low levels in the globus pallidus, the substantia nigra and the aT~ygdala, Densities in other regions examined were very low to absent, The results indicated that 5-HT7 receptors are most abundantly localized in the anterior thalamus and in the dentate gyrus with intermediate levels in the hypothalamus, anterior cingulate gyrus, hippocampus and amygdala. Concision-" The 5-HT~ receptor is concentrated in the striatum of the human brain with low levels in other forebrain regions. 5-HT7 receptors are most abundantly localized in the anterior thalamus, the hippocampai formation, the anterior cingulate gyrus,
$3 60
[2] Blacker, D., Wilcox, M.A., Laird, N.M., Redes, L., Horvath, S.M., Go. R., etal. : Alpha-2 macroglobulin is genetically associated with AlzheimePs disease. Nat. Goner., 1998; 19: 357-360. [3] MoKeith, I.G., Ballard, C.G., Perry, R.H., Inca, RG., O'Brien, J.q2, Neill, D., etal. : Prospective validation of conceusus criteria for the diagnosis od dementia with Lewd bodies. Neurology, 2000; 54:10G0-1058.
•
Treatment of pain, depressive and anxiety symptoms in fibromyalgia with venlafaxine
B, Evren 1, C, Evren 2., M. Hosafci Guler 3 . 1Baltalimani State Hospital for Muskaloskeletal Disorders, Consultant Peyehiatrist, Istanbul, Turkey; 2Bakirkoy &ate Hospital for Mental Health and Neurological Disorders, AMATEM, Istanbal, Turkey; 3Ba#alimani State Hosp#al for Muskuloskeletal Disorders, P1weieal Therapy and ~ehab#itation Specialist, IxtanbuL Turkey
Objective: Although the pathophysiology of fibromyalgia is unknown, antidepressants have proved to be successful in alleviating symptorn~ of fibromyalgia. Aim of this study was to evaluate the efficacy of veniafaxine in the treatment of patients with fibromyaigia and depressive and anxiety symptoms commonly seen with these patients, 1VI.ethod: The study was conducted between October 2003 and March 200,4 in Naltalimani State Hospital for Musculoskeletal Disorders in Istanbuh Twenty patients with fibrorrryalgia according to the operational criteria proposed by the American College of Rheumatology were included in the study. Patients were assessed prior to and after trea~nent with fixed dose venlafaxine 75 mgtd. Second and third evaluations were in weeks 5 and 10. Pain were measured by visual analog scale and verbal analog scale and the anxiety and depression levels were measured by the Beck Depression, the Deck Anxiety, the Hamilton Anxiety and the Hamilton Depression scales. Remlts" There was a significant improvement in the mean intensity of pain and in depression and anxiety scores from baseline to week 5 and 10. The improvement in pain scores were correlated with the decrease of somatic anxiety scores measured with Hamilton Anxiety Scale. C ~ n e l ~ i o m Venlafaxine a potent inhibitor of both norepinephrine and serotonin reuptake, might be effective for both pain and comorbid depressive and anxiety symptoms independently in patients with fibromyalgia. References
O'Malley PO, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Trea~nent of fibromyalgia with antidepressants: a mats-analysis. J Gen Intern Mad. 2000 Sep;15(9):659-66. Dwi~t MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr. An open clinical trial of venlafaxine treatment of fibrornyalgia. Psy&osomatios. 1998 Jan-Feb;39(1): 14-7. Sayar K, Alcsu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Phan'nacother. 2003 Nov;37(ll):1561-5.
•
Bright light treatment in anorexia nervosa
M. Janas-Kozik 1, I. Krupka-Matuszcayk 1, M. Krzystanek 1, H i . Trzeciak 2, J . Szyrn~zal 1 . 1Nlesian Medical University,
Department and Clinic of Psychiatry and Psychotherapy, Katowice, Poland; 2Silesian Medic~ Unioersi~ Department of 2harmacology, Zatowice, Poland Bright light treatment (-BLT) was introduced for the first time to a treaCnent of seasonal affeotive disorder. Bright light synchronizes biological rhythms of human and increases serotoninergic
transmission in a brain [1], Anorexia nervosa (AN-) is a disorder with a putative increase of serotoninergic activity, Characteristic symptoms of A N are aberrant eating behavior, a desire to lose weight and fear of becoming obese, The theoretical assumption that BET may improve ~ m p t o m s of A N has never been explored be%re, The aim of the study was to assess an influence of BLT on body mass changes in AN patients during a 6 weeks of treatment, 26 female A N patients aged from 12-22 years were the examined group. 9 patients were treated with BLT and 17 were a control group. Every subsequent week of treatment the body mass index (BN3) and BMI changes were calculated and depressive symptoms assessed using Hamilton rating scale. BMI increases in each of the examined groups were observed (p<0,001). There were not statistically significant differences between BMI increases in the examined groups. A N patients with depressive symptoms showed improvement after 6 weeks (1:>=0.028). DLT may be considered effectNe in a treatment of depressive symptoms in AN. References
[1] Metzger JY, Berthou V, P~'rin P, Siohel JP (1998): Phototherapy: dininal and therapeutic evaNation of a 2-year e~perieuce. Eneephale 199% 24: 480-485. [2] Ericsson M., Poston II W.S.C., Foreyt J.F:: Common biological pathways in eating disorders and obesity. Addict. Behav. 1996, 21: 733-743.
•
Distribution of 5-HTs and 5-HT7 receptors in the human brain
K. Varnh,s 1, D.R. Thornas 2, W.D. Hirst 3, H, Hall l . 1Karolinska Instituter, Clinical Neuroscience, Psychiatry Section, Stockholm, Sweden," 2 glaxo~qm#hKline, Psychiatry Centre of Exce~ence for Drug Discovery, Harlow, United Kingdom; 3~Yyeth lResearch, Neurodegeneration Research, Princeton, N J, US.A. Purpose: The 5-HT~ and 5-HT7 receptor subtypes have been implicated in the mechanisms underlying a number of psychiatric disorders, These receptor subtypes have been suggested to be of interest for the mechanism of action of antipsychotic drugs due to the high affinity of clozapine for these binding sites, 5-HT7 receptors have also been irrplicated in anxiety and unipolar depression, Furthermore, there is evidence for the involvement of 5-HT~ and 5-HT7 receptors in cognitive functions, The aim of this study was to investigate the autoradiographio distribution of 5-HT~ and 5-HT7 receptors in the human brain, Information on the specific distribution patterns of these receptor subtypes in the human brain may clarify the different physiological functions mediated by these receptors, M.ethods: The selective and high affinity radioligands [125I]SB258585 and [IH]SB-269970 were used to study the autoradiographic distribution of 5-HT6 and 5-HT7 receptor subtypes, respectivety, in human brain whole hemisphere cryosections, Results: The 5-HT~ receptor binding sites were highly concentrated in the striatum with low levels in the globus pallidus, the substantia nigra and the aT~ygdala, Densities in other regions examined were very low to absent, The results indicated that 5-HT7 receptors are most abundantly localized in the anterior thalamus and in the dentate gyrus with intermediate levels in the hypothalamus, anterior cingulate gyrus, hippocampus and amygdala. Concision-" The 5-HT~ receptor is concentrated in the striatum of the human brain with low levels in other forebrain regions. 5-HT7 receptors are most abundantly localized in the anterior thalamus, the hippocampai formation, the anterior cingulate gyrus,